Search results
Results from the WOW.Com Content Network
On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...
Prior to the IPO, it had $62 million in cash and equivalents on its balance sheet. The IPO raised approximately $167 million. So, it should now have around $229 million in cash, a little over four ...
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies.
For premium support please call: 800-290-4726 more ways to reach us
In July 2015, Soon-Shiong initiated an IPO for NantKwest (formerly ConkWest) that represented the highest value biotech IPO in history, at a market value of $2.6 billion. [50] In April 2016, the Los Angeles Times reported that Soon-Shiong received a pay package in 2015 from NantKwest worth almost $148 million, making him one of the highest paid ...
[citation needed] Avalanche went public through an IPO in 2014, raising $102 million. [6] In 2015, co-founder Tom Chalberg stepped down as CEO following Phase IIa trial results that were labeled as "iffy". [7] In May 2016, Avalanche acquired Annapurna Therapeutics and changed its name to Adverum Biotechnologies. [8]
Lighter Side. Medicare. News